Skip to main content

Advertisement

SpringerLink
Log in

Management of Respiratory Symptoms Induced by Non-Steroidal Anti-Inflammatory Drugs

  • Drug Allergy (MJ Torres Jaén, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Opinion Statement

Non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (NERD) is defined by the combination of chronic rhinosinusitis, nasal polyps, bronchial asthma, and hypersensitivity reactions involving upper and/or lower airways after the exposure to acetylsalicylic acid (ASA) and other NSAIDs. However, airway inflammation occurs even in the absence of exposure to these drugs, leading to disease progression with aggressive polyp formation and non-optimal controlled asthma and rhinosinusitis. In this review, we discuss current and potential management strategies of NERD. This management should be multidisciplinary and comprise medical and surgical treatment of the underlying diseases. In order to prevent reactions due to NSAIDs, avoidance of COX-1 inhibitors with provision of safe therapeutic alternatives should be indicated. However, avoidance of NSAIDs does not ensure disappearance of the airway inflammation and this progresses and persists for life. ASA desensitization followed by daily ASA therapy remains the gold standard of NERD treatment. It is indicated in patients with uncontrolled bronchial and nasal symptoms as well as in patients who require NSAID treatment for specific diseases, such as rheumatic or cardiovascular conditions. ASA desensitization improves upper and lower respiratory symptoms, reduces the need for new nasal surgeries and increases quality of life. Different ASA desensitization protocols have been reported, although the addition of intranasal ketorolac and lysine aspirin prior to an oral ASA schedule has made ASA desensitization safer and more efficient. New therapeutic strategies are being investigated and may provide an alternative treatment for those patients in which ASA desensitization are contraindicated or continuous ASA therapy is discontinued because of adverse effects. Among them, biologic agents are an important treatment option, useful for controlling symptoms of the upper and lower airways. More investigation studies into the mechanisms involved in NERD are needed in order to identify additional therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Quiralte J et al. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996;98(3):678–85.

    Article  CAS  PubMed  Google Scholar 

  2. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89(5):474–8.

    Article  PubMed  Google Scholar 

  3. •• Stevenson DD, White AA. Clinical characteristics of aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):643–55. This paper reviews the characteristic features of patients with NERD. Features that suggest a diagnosis of NERD include severe sinus, polyp recurrence postoperatively, marked anosmia, alcohol intolerance and hypersensitivity reactions to ASA or other NSAIDs.

    Article  PubMed  Google Scholar 

  4. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16(3):432–6.

    Article  CAS  PubMed  Google Scholar 

  5. Walters KM, Woessner KM. An overview of nonsteroidal antiinflammatory drug reactions. Immunol Allergy Clin North Am. 2016;36(4):625–41.

    Article  PubMed  Google Scholar 

  6. • Rajan JP et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81 e1. This metanalysis determines the prevalence of NERD among asthmatic adults, being higher among patients with severe asthma, nasal polyps and chronic rhinosinusitis.

    Article  CAS  PubMed  Google Scholar 

  7. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mascia K et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116(5):970–5.

    Article  CAS  PubMed  Google Scholar 

  9. Choi JH, Kim MA, Park HS. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014;14(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  10. Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol. 2006;147(7):707–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Liu T et al. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013;110(42):16987–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46(8):2201–6.

    Article  CAS  PubMed  Google Scholar 

  13. Choi JH, Kim JH, Park HS. Upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2015;15(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  14. Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33(2):163–76.

    Article  PubMed  Google Scholar 

  15. Nizankowska-Mogilnicka E et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62(10):1111–8.

    Article  CAS  PubMed  Google Scholar 

  16. Miller B et al. Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis. Clin Exp Allergy. 2013;43(8):874–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Becker AB, Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol, 2017.

  18. National Asthma, E. andP. Prevention Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma-summary report. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–138.

    Google Scholar 

  19. • Macy E et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172–4. In this paper, Macy et al. describe protocols and requirements for ASA desensitization and challenge and discussed the prechallenge of patients and maintenance of ASA desensitization.

    Article  CAS  PubMed  Google Scholar 

  20. Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15(3):508.

    Article  PubMed  CAS  Google Scholar 

  21. •• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–40. quiz 1441. This paper reviews current and future treatments for rhinosinusitis, including classical paharmacotherapy options such as glucocorticosteroids and antibiotics, as well as new approaches including humanized monoclonal antibodies: omalizumab, reslizumab, mepolizumab and dupilumab.

    Article  CAS  PubMed  Google Scholar 

  22. Waldram JD, Simon RA. Performing aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):693–703.

    Article  PubMed  Google Scholar 

  23. Ledford DK, Lockey RF. Aspirin or nonsteroidal anti-inflammatory drug-exacerbated chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):590–8.

    Article  PubMed  Google Scholar 

  24. Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133(1):286–7. e1-9.

    Article  CAS  PubMed  Google Scholar 

  25. Kim YJ et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy, Asthma Immunol Res. 2014;6(2):156–62.

    Article  CAS  Google Scholar 

  26. Neubauer PD, Schwam ZG, Manes RP. Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with polyposis after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016;6(3):233–7.

    Article  PubMed  Google Scholar 

  27. Mastalerz L et al. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy. 1997;52(9):895–900.

    Article  CAS  PubMed  Google Scholar 

  28. Martinez-Devesa P, Patiar S. Oral steroids for nasal polyps. Cochrane Database Syst Rev. 2011;7:CD005232.

    Google Scholar 

  29. Van Zele T et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069–76. e4.

    Article  PubMed  CAS  Google Scholar 

  30. Lal D, Hwang PH. Oral corticosteroid therapy in chronic rhinosinusitis without polyposis: a systematic review. Int Forum Allergy Rhinol. 2011;1(2):136–43.

    Article  PubMed  Google Scholar 

  31. Aasbjerg K et al. Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes. Respir Med. 2013;107(12):1852–8.

    Article  PubMed  Google Scholar 

  32. Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol. 2006;126(11):1195–200.

    Article  CAS  PubMed  Google Scholar 

  33. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991;144(4):957–8.

    Article  CAS  PubMed  Google Scholar 

  34. Nasser SM et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 1994;49(8):749–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dahlen SE et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9–14.

    Article  PubMed  Google Scholar 

  36. Lee DK et al. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J. 2004;24(2):226–30.

    Article  CAS  PubMed  Google Scholar 

  37. Israel E et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148(6 Pt 1):1447–51.

    Article  CAS  PubMed  Google Scholar 

  38. Dahlen B et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1187–94.

    Article  CAS  PubMed  Google Scholar 

  39. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(5):711–8.

    Article  PubMed  Google Scholar 

  40. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002;32(10):1491–6.

    Article  CAS  PubMed  Google Scholar 

  41. White A et al. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol. 2006;97(5):688–93.

    Article  CAS  PubMed  Google Scholar 

  42. Ragab S et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31(9):1385–91.

    Article  CAS  PubMed  Google Scholar 

  43. Peters AT et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113(4):347–85.

    Article  PubMed  Google Scholar 

  44. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S-50S. quiz 51S.

    Google Scholar 

  45. Wallwork B et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189–93.

    Article  CAS  PubMed  Google Scholar 

  46. Videler WJ et al. Long-term low-dose antibiotics in recalcitrant chronic rhinosinusitis: a retrospective analysis. Rhinology. 2012;50(1):45–55.

    CAS  PubMed  Google Scholar 

  47. Campo P et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy. 2013;68(8):1001–7.

    Article  CAS  PubMed  Google Scholar 

  48. Buchheit KM, Laidlaw TM. Update on the management of aspirin-exacerbated respiratory disease. Allergy, Asthma Immunol Res. 2016;8(4):298–304.

    Article  Google Scholar 

  49. Sakalar EG et al. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol, 2016.

  50. Khalil HS, Nunez DA. Functional endoscopic sinus surgery for chronic rhinosinusitis. Cochrane Database Syst Rev. 2006;3:CD004458.

    Google Scholar 

  51. Dalziel K et al. Endoscopic sinus surgery for the excision of nasal polyps: a systematic review of safety and effectiveness. Am J Rhinol. 2006;20(5):506–19.

    Article  PubMed  Google Scholar 

  52. Awad OG et al. Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? Laryngoscope. 2008;118(7):1282–6.

    Article  PubMed  Google Scholar 

  53. Joint Task Force on Practice P. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73.

    Article  Google Scholar 

  54. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–6.

    Article  CAS  PubMed  Google Scholar 

  55. Stevenson DD et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996;98(4):751–8.

    Article  CAS  PubMed  Google Scholar 

  56. Kowalski ML et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–32.

    Article  CAS  PubMed  Google Scholar 

  57. White AA, Stevenson DD. Aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33(2):211–22.

    Article  PubMed  Google Scholar 

  58. Sweet JM et al. Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol. 1990;85(1 Pt 1):59–65.

    Article  CAS  PubMed  Google Scholar 

  59. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119(1):157–64.

    Article  CAS  PubMed  Google Scholar 

  60. Cho KS et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575–81.

    Article  PubMed  Google Scholar 

  61. Makowska JS et al. Clinical benefits of aspirin desensitization in patients with nonsteroidal anti-inflammatory drug exacerbated respiratory disease are not related to urinary eicosanoid release and are accompanied with decreased urine creatinine. Allergy Asthma Proc. 2016;37(3):216–24.

    Article  PubMed  Google Scholar 

  62. Rozsasi A et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228–34.

    Article  CAS  PubMed  Google Scholar 

  63. Stevenson DD et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984;73(4):500–7.

    Article  CAS  PubMed  Google Scholar 

  64. Swierczynska-Krepa M et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014;134(4):883–90.

    Article  CAS  PubMed  Google Scholar 

  65. Fruth K et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68(5):659–65.

    Article  CAS  PubMed  Google Scholar 

  66. Comert S et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy. 2013;68(11):1443–51.

    Article  CAS  PubMed  Google Scholar 

  67. Havel M et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2013;270(2):571–8.

    Article  PubMed  Google Scholar 

  68. Esmaeilzadeh H et al. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial. Clin Immunol. 2015;160(2):349–57.

    Article  CAS  PubMed  Google Scholar 

  69. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003;90(3):338–41.

    Article  CAS  PubMed  Google Scholar 

  70. Kowalski ML, Wardzynska A, Makowska JS. Clinical trials of aspirin treatment after desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):705–17.

    Article  PubMed  Google Scholar 

  71. Patriarca G et al. Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy. 1991;67(6):588–92.

    CAS  PubMed  Google Scholar 

  72. Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121(12):1156–60.

    Article  CAS  PubMed  Google Scholar 

  73. Howe R et al. Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease. World Allergy Organ J. 2014;7(1):18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Steinke JW et al. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol. 2009;124(4):724–30. e4.

    Article  CAS  PubMed  Google Scholar 

  75. Katial RK et al. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010;126(4):738–44.

    Article  CAS  PubMed  Google Scholar 

  76. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118(4):801–4.

    Article  PubMed  Google Scholar 

  77. Hope AP et al. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123(2):406–10.

    Article  CAS  PubMed  Google Scholar 

  78. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep. 2009;9(2):155–63.

    Article  CAS  PubMed  Google Scholar 

  79. Cook KA, Stevenson DD. Current complications and treatment of aspirin-exacerbated respiratory disease. Expert Rev Respir Med. 2016;10(12):1305–16.

    Article  CAS  PubMed  Google Scholar 

  80. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;95(4):330–5.

    Article  CAS  PubMed  Google Scholar 

  81. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24(2):159–68.

    Article  CAS  PubMed  Google Scholar 

  82. • Lee RU et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105(2):130–5. In this paper the authors compared standard oral ASA desensitization and intranasal ketorolac followed by modified oral ASA desensitization, showing that the use of intranasal ketorolac followed by oral ASA induced fewer lower respiratory reactions, making this protocol effective, safe, and less time-consuming than the standard oral ASA desensitization protocol.

    Article  CAS  PubMed  Google Scholar 

  83. • Chen JR, Buchmiller BL, Khan DA. An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(6):926–31 e1. In this paper a 1-hour dose-escalation protocol for desensitization patients with NERD is proposed.

    Article  PubMed  Google Scholar 

  84. Williams AN et al. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007;120(2):273–7.

    Article  CAS  PubMed  Google Scholar 

  85. Stevenson DD, White AA. Aspirin desensitization in aspirin-exacerbated respiratory disease: consideration of a new oral challenge protocol. J Allergy Clin Immunol Pract. 2015;3(6):932–3.

    Article  PubMed  Google Scholar 

  86. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy, Asthma Immunol Res. 2011;3(1):3–10.

    Article  CAS  Google Scholar 

  87. Simon RA, Dazy KM, Waldram JD. Aspirin-exacerbated respiratory disease: characteristics and management strategies. Expert Rev Clin Immunol. 2015;11(7):805–17.

    Article  CAS  PubMed  Google Scholar 

  88. White AA, Stevenson DD. Side effects from daily aspirin treatment in patients with AERD: identification and management. Allergy Asthma Proc. 2011;32(5):333–4.

    Article  PubMed  Google Scholar 

  89. Schjerning Olsen AM et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ. 2015;351:h5096.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Segal R et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med. 2003;115(6):462–6.

    Article  CAS  PubMed  Google Scholar 

  91. • Gevaert P et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6 e1. This study demonstrates the clinical efficacy of omalizumab in the treatment of nasal polyps with comorbid asthma.

    Article  CAS  PubMed  Google Scholar 

  92. Humbert M et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2(5):525–36 e1.

    Article  PubMed  Google Scholar 

  93. Bobolea I et al. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol. 2010;20(5):448–9.

    CAS  PubMed  Google Scholar 

  94. Guillen D et al. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease. J Investig Allergol Clin Immunol. 2015;25(2):133–5.

    CAS  PubMed  Google Scholar 

  95. Bergmann KC, Zuberbier T, Church MK. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):459–60.

    Article  PubMed  Google Scholar 

  96. Menzella F et al. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy. 2015;8:105–14.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Gevaert P et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95. e1-8.

    Article  CAS  PubMed  Google Scholar 

  98. Gevaert P et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003;58(5):371–9.

    Article  CAS  PubMed  Google Scholar 

  99. Simon HU et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol. 1997;158(8):3902–8.

    CAS  PubMed  Google Scholar 

  100. Thaci D et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.

    Article  CAS  PubMed  Google Scholar 

  101. Wenzel S et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.

    Article  CAS  PubMed  Google Scholar 

  102. Pitchford SC et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol. 2003;112(1):109–18.

    Article  CAS  PubMed  Google Scholar 

  103. Laidlaw TM et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Klinkhardt U et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003;73(3):232–41.

    Article  CAS  PubMed  Google Scholar 

  105. Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(6):1407–14. quiz 1415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Lupinetti MD et al. Thromboxane biosynthesis in allergen-induced bronchospasm. evidence for platelet activation. Am Rev Respir Dis. 1989;140(4):932–5.

    Article  CAS  PubMed  Google Scholar 

  107. Schumacher WA, Steinbacher TE. Thromboxane receptor activation during bronchospasm induced by platelet-activating factor. J Lipid Mediat. 1991;4(1):97–110.

    CAS  PubMed  Google Scholar 

  108. Bochenek G et al. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003;111(4):743–9.

    Article  CAS  PubMed  Google Scholar 

  109. Hirai H et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193(2):255–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Nagata K, Hirai H. The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2–3):169–77.

    Article  CAS  PubMed  Google Scholar 

  111. Uller L et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007;8:16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Allergy Unit, Malaga Regional University Hospital, Pabellón 6, primera planta, Plaza del Hospital Civil, 29009, Malaga, Spain

    Inmaculada Doña MD, PhD, María Salas MD, PhD, Esther Barrionuevo MD, PhD & Paloma Campo MD, PhD

Authors
  1. Inmaculada Doña MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Salas MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Esther Barrionuevo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paloma Campo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Inmaculada Doña MD, PhD.

Ethics declarations

Conflict of Interest

Inmaculada Doña, María Salas, Esther Barrionuevo and Paloma Campo declare that they have no conflict of interest. The present study has been supported by the Andalusian Regional Ministry Health (grant: PI-0463-2013). Inmaculada Doña holds a “Juan Rodes” research contract (JR15/00036) supported from the Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness, RETIC ARADYAL (RD16/0006/0001) (grants cofunded from the European Social Fund (ESF)).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Drug Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doña, I., Salas, M., Barrionuevo, E. et al. Management of Respiratory Symptoms Induced by Non-Steroidal Anti-Inflammatory Drugs. Curr Treat Options Allergy 4, 268–282 (2017). https://doi.org/10.1007/s40521-017-0129-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-017-0129-1

Keywords

Search

Navigation